Diabetes Mellitus Reduces Prostate Cancer Risk - No Function of Age at Diagnosis or Duration of Disease

Xu, Hua; Mao, Shanhua; Ding, Guanxiong; Ding, Qiang; Jiang, Haowen

doi:10.7314/apjcp.2013.14.1.441

Cited by 13 publications

(7 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our analysis, similar to the data published by Turner et al, didn't show any association between T2DM duration and risk of prostate cancer [22]. Xu et al, in meta-analysis of 29 studies didn't find statistically significant associations between length of T2DM duration and prostate cancer risk (p=0.338) as well [23]. On the other hand, investigators from USA have reported that the strength of diabetes and prostate cancer inverse association differed significantly by time since diagnosis of diabetes and increases with longer duration of diabetes; risk of prostate cancer was slightly increased during the first 3 years after diagnosis of diabetes, but was reduced among men diagnosed 4 or more years before [24].…”

Section: Discussionsupporting

confidence: 90%

Reduced risk of prostate cancer in a cohort of Lithuanian diabetes patients

Kincius¹,

Patašius²,

Linkeviciute-Ulinskiene³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: The aim of this study was to determine whether type 2 diabetes mellitus and treatment with metformin is associated with prostate cancer risk. Methods: Male patients with diagnosis of type 2 diabetes during the period of 2000 – 2016 were identified in the National Health Insurance Fund database. The prostate cancer cases were identified by pooling these records from the national Cancer Registry. The calculation of prostate cancer stardardized incidence ratios (SIRs) was composed as a ratio of observed number of cancer case in people with diagnosis of diabetes to the expected number of cancer cases in the underlying general population. Results: Overall, 64,000 males diagnosed with diabetes in Lithuania between 2000 and 2016 were included in the final cohort. 2,754 prostate cancers were observed versus 3,111.26 expected within the period of observation entailing an SIR of 0.89 (95% CI: 0.85–0.92). Significantly lower risk of prostate cancer was found in diabetes patients in all age groups, there were no differences in prostate cancer risk by time since diagnosis of diabetes. Significantly lower risk of prostate cancer also was found in both metformin users and never-users’ groups, with higher risk reduction in metformin users (SIR 0.71, 95% CI: 0.68–0.75) than in diabetes patients never-users (SIR 0.88, 95% CI: 0.80–0.96). Conclusions: In this large population-based study we found a significantly decreased risk of prostate cancer among men with diabetes and metformin users. However, the risk of prostate cancer showed no clear trend with diabetes duration and cumulative metformin dose.

show abstract

Section: Discussionsupporting

confidence: 90%

Reduced risk of prostate cancer in a cohort of Lithuanian diabetes patients

Kincius¹,

Patašius²,

Linkeviciute-Ulinskiene³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Conversely, factors associated with a lower rate of PSA testing have been associated with a lower risk of prostate cancer, such as obesity [14], diabetes [15], being of Asian ethnic origin [16] and smoking [17]. This suggests that the magnitude of associations observed with risk of total prostate cancer for established risk factors such as black ethnic origin and family history might be exaggerated in recent studies, whereas less well-established associations (such as those between dietary factors and prostate cancer risk), might be due to detection bias.…”

Section: Discussionmentioning

confidence: 99%

Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research

Littlejohns

Travis

Key

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

show abstract

“…DM can increase the risk of cancer in many organs such as pancreas, liver, breast, thyroid, urinary bladder and endometrium (review in [5]). DM, however, was shown to reduce risk of prostate cancer [4,5,[19][20][21]. For CCA, many epidemiological studies indicated DM as a risk of CCA ( Table 1).…”

Section: Epidemiological Studies Revealed Dm As a Risk Factor Of Ccamentioning

confidence: 98%